203 related articles for article (PubMed ID: 9863652)
1. The antihypertensive profile of the angiotensin AT1 receptor antagonist, GR138950, and the influence of potential homeostatic compensatory mechanisms in renal hypertensive rats.
Anderson IK; Drew GM
Br J Pharmacol; 1998 Nov; 125(6):1236-46. PubMed ID: 9863652
[TBL] [Abstract][Full Text] [Related]
2. Investigation of the inhibitory effect of N(G)-nitro-L-arginine methyl ester on the antihypertensive effect of the angiotensin AT1 receptor antagonist, GR138950.
Anderson IK; Drew GM
Br J Pharmacol; 1997 Dec; 122(7):1385-94. PubMed ID: 9421286
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist.
Hilditch A; Hunt AA; Travers A; Polley J; Drew GM; Middlemiss D; Judd DB; Ross BC; Robertson MJ
J Pharmacol Exp Ther; 1995 Feb; 272(2):750-7. PubMed ID: 7853190
[TBL] [Abstract][Full Text] [Related]
4. Development of high sodium renal hypertension during chronic blockade of the vascular effects of vasopressin.
Hinojosa C; Haywood JR
J Pharmacol Exp Ther; 1986 Aug; 238(2):492-6. PubMed ID: 2874211
[TBL] [Abstract][Full Text] [Related]
5. Further investigations into the mechanism of the antihypertensive activity of the angiotensin AT1 receptor antagonist, GR138950.
Hilditch A; Prior HM; Drew GM
Br J Pharmacol; 1996 Jun; 118(3):711-9. PubMed ID: 8762098
[TBL] [Abstract][Full Text] [Related]
6. Vasopressin: mechanism of central cardiovascular action in conscious rats.
Rohmeiss P; Becker H; Dietrich R; Luft F; Unger T
J Cardiovasc Pharmacol; 1986; 8(4):689-96. PubMed ID: 2427805
[TBL] [Abstract][Full Text] [Related]
7. Peripheral mechanisms involved in the pressor and bradycardic effects of centrally administered arachidonic acid.
Aydin C; Yalcin M
Prostaglandins Leukot Essent Fatty Acids; 2008 Jun; 78(6):361-8. PubMed ID: 18571395
[TBL] [Abstract][Full Text] [Related]
8. Effects of the angiotensin AT1 receptor antagonist GRI38950 on haemodynamic function in dogs.
Hunt AA; Hilditch A; Drew GM
J Auton Pharmacol; 1997 Feb; 17(1):1-11. PubMed ID: 9201554
[TBL] [Abstract][Full Text] [Related]
9. Influence of arginine vasopressin receptors and angiotensin receptor subtypes on the water intake and arterial blood pressure induced by vasopressin injected into the lateral septal area of the rat.
Abrão Saad W; Antonio De Arruda Camargo L; Sérgio Cerri P; Simões S; Abrão Saad W; Garcia G; Izabel Gutierrez L; Guarda I; Saad Guarda R
Auton Neurosci; 2004 Mar; 111(1):66-70. PubMed ID: 15109940
[TBL] [Abstract][Full Text] [Related]
10. Chronic salt loading and cardiovascular-associated changes in experimental diabetes in rats.
Maeda C; Schaan B; Oliveira E; Oliveira V; De Angelis K; Irigoyen M
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):574-80. PubMed ID: 17581211
[TBL] [Abstract][Full Text] [Related]
11. Effects of losartan, prazosin and a vasopressin V1-receptor antagonist on renal and femoral blood flow in conscious sheep.
Ullman J; Eriksson S; Rundgren M
Acta Physiol Scand; 2001 Jan; 171(1):99-104. PubMed ID: 11350268
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular effects of centrally administered arachidonic acid in haemorrhage-induced hypotensive rats: investigation of a peripheral mechanism.
Yalcin M; Aydin C
Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):447-53. PubMed ID: 19702598
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular effects of intracerebroventricularly injected CDP-choline in normotensive and hypotensive animals: the involvement of cholinergic system.
Savci V; Cavun S; Goktalay G; Ulus IH
Naunyn Schmiedebergs Arch Pharmacol; 2002 May; 365(5):388-98. PubMed ID: 12012025
[TBL] [Abstract][Full Text] [Related]
14. Centrally administered interleukin-1 beta sensitizes to the central pressor action of angiotensin II.
Ufnal M; Dudek M; Zera T; Szczepańska-Sadowska E
Brain Res; 2006 Jul; 1100(1):64-72. PubMed ID: 16765325
[TBL] [Abstract][Full Text] [Related]
15. Lack of effect of a selective vasopressin V1A receptor antagonist SR 49,059, on potentiation by vasopressin of adrenoceptor-mediated pressor responses in the rat mesenteric arterial bed.
Heinemann A; Horina G; Stauber RE; Pertl C; Holzer P; Peskar BA
Br J Pharmacol; 1998 Nov; 125(6):1120-7. PubMed ID: 9863637
[TBL] [Abstract][Full Text] [Related]
16. Effects of intracerebroventricularly injected glucagon-like peptide-1 on cardiovascular parameters; role of central cholinergic system and vasopressin.
Isbil-Buyukcoskun N; Gulec G
Regul Pept; 2004 Apr; 118(1-2):33-8. PubMed ID: 14759554
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure.
Brooks DP; Ruffolo RR
J Hypertens Suppl; 1999 Jun; 17(2):S27-32. PubMed ID: 10465064
[TBL] [Abstract][Full Text] [Related]
18. [Activation of the renin-angiotensin system and blood pressure variability in rats].
Blanc J; Lambert G; Elghozi JL
Arch Mal Coeur Vaiss; 2000 Aug; 93(8):1019-22. PubMed ID: 10989749
[TBL] [Abstract][Full Text] [Related]
19. Sympathetic activation following central vasopressin receptor stimulation in conscious rats.
Unger T; Rohmeiss P; Becker H; Ganten D; Lang RE; Petty M
J Hypertens Suppl; 1984 Dec; 2(3):S25-7. PubMed ID: 6100738
[TBL] [Abstract][Full Text] [Related]
20. Sympatho-inhibitory properties of various AT1 receptor antagonists.
Balt JC; Mathy MJ; Pfaffendorf M; van Zwieten PA
J Hypertens Suppl; 2002 Jun; 20(5):S3-11. PubMed ID: 12184061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
